Binodenoson Phase II Clinical Data to be Presented at American Heart Association Scientific Sessions by King Pharmaceuticals
Results indicate that binodenoson, an adenosine A2A receptor agonist for cardiac pharmacologic stress-imaging, appears to detect myocardial ischemia a well as adenosine, while minimizing side effects like heart block, dyspnea and chest pain.
Hopkinton, MA - Oct 24, 2003 - Aderis Pharmaceutical's partner for binodenoson, King Pharmaceuticals, reports that one poster and two oral presentations of the findings of the Phase II trials for binodenoson will be presented at the American Heart Association Scientific Sessions, November 9-12, 2003 in Orlando, Florida. Read the complete release from King.
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
